Orient Pharma Co., Ltd.

TPEX:4166 Stock Report

Market Cap: NT$5.6b

Orient Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chun-Tong Huang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.1%
Management average tenureno data
Board average tenure8.8yrs

Recent management updates

Recent updates

Analysis Article • Mar 22

Is Orient Pharma (GTSM:4166) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jan 28

What Type Of Returns Would Orient Pharma's(GTSM:4166) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
Analysis Article • Dec 07

Does Orient Pharma (GTSM:4166) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

CEO

Chun-Tong Huang

no data
Tenure

Mr. Chun-Tong Huang serves as General Manager of Orient Pharma Co., Ltd.

Board Members

NamePositionTenureCompensationOwnership
Calvin Tsai
Directorno datano data0.74%
NT$ 41.3m
Phoebe Lee
Directorno datano data0.12%
NT$ 6.7m
Wei-Chao Kao
Directorno datano datano data
Wen-Foung Huang
Directorno datano datano data
Han-Liang Hu
Supervisorno datano datano data
Chih-Chen Cho
Supervisorno datano datano data
Hua-Ming Lin
Independent Directorno datano datano data
Ko-Hsin Hu
Director8.8yrsno datano data
Thomas Chen
Independent Director8.8yrsno datano data
Amy Huang
Independent Director8.8yrsno datano data
Cheng Hong Ma
Supervisor8.8yrsno datano data
Zheng Hong Cai
Chairmanno datano datano data
8.8yrs
Average Tenure

Experienced Board: 4166's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 06:32
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Orient Pharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.